Mirta Dumančić

Mirta Dumančić

Auto-generated profile, based on publicly available information

Mirta Dumančić

Medical Physics Unit, Department of Oncology, Faculty of Medicine McGill University Montréal Québec Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Physica Medica
Verified
Journal Article
Closed access
MDMario Djukelic
Mario Djukelic
CMColin John John Martin
Colin John John Martin
AAAbdullah Abuhaimed
Abdullah Abuhaimed
Tomas KronTomas Kron
Tomas Kron
SGSebastien Gros
Sebastien Gros
WSWilliam C. Small
William C. Small

15 July 2025 in Medical Physics
Verified
Journal Article
Open access
MDMirta Dumančić
Mirta Dumančić
JKJonathan Kalinowski
Jonathan Kalinowski
VDVictor D. Diaz‐Martinez
Victor D. Diaz‐Martinez
JLJoanna Li
Joanna Li
BBBehnaz Behmand
Behnaz Behmand
SEShirin A. Enger
Shirin A. Enger
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.

1 May 2026 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
MDMirta Dumančić
Mirta Dumančić
YZYujing Zou
Yujing Zou
HGHarry Glickman
Harry Glickman
SKSara Ghassimi Kouraneh
Sara Ghassimi Kouraneh
PPPiotr Pater
Piotr Pater
SEShirin A. Enger
Shirin A. Enger
Brachytherapy is a highly conformal and cost-effective radiotherapy modality, yet its clinical utilization has declined in multiple regions. This study investigated trends in brachytherapy utilization across different Canadian provinces from 2011 to 2020. A national survey was distributed to medical physicists in cancer centres across ten Canadian provinces, collecting data on types of brachytherapy, annual number of treatments, clinical indications, and logistical factors. In Québec, treated clinical indications were obtained through a complementary survey of all radiotherapy centres, extending previously published provincial brachytherapy data. Out of 39 radiotherapy centres in Canada conducting brachytherapy treatments, 25 centres were included in this study. HDR accounted for the majority of treatments (60%–100%) and increased in most provinces, while LDR declined across reporting provinces; PDR comprised ≤10% of treatments and was limited to Alberta and Ontario. After adjusting for indication-specific cancer incidence and combining HDR and LDR brachytherapy, utilization trends showed decreases in Alberta and British Columbia, increases in Ontario, Nova Scotia, and Saskatchewan, and no significant change in Manitoba, Québec, or nationally. This study revealed significant regional variations in brachytherapy utilization and clinical practices across Canadian radiotherapy centres. Factors influencing these trends include reimbursement structures, personnel and infrastructure availability, and clinician preferences. The use of HDR modalities is increasing nationally, while LDR is declining. Despite significant regional differences, brachytherapy utilization in Canada was largely sustained over the decade from 2011 to 2020.

16 June 2025 in Physics in Medicine & Biology
Verified
Journal Article
Open access
NCNaim Chabaytah
Naim Chabaytah
MDMirta Dumančić
Mirta Dumančić
EAEmmanuel C. Asante
Emmanuel C. Asante
TCTanner Connell
Tanner Connell
MWMichael Witcher
Michael Witcher
SEShirin Abbasinejad Enger
Shirin Abbasinejad Enger
Objective. This study aimed to determine whether the kinetics of sublethal damage recovery after x-ray irradiation, quantified as the repair half time ( T repair SLD ) derived from split-dose clonogenic survival, correlates with intrinsic radiosensitivity across four human cancer cell lines: HeLa (cervical), PC3 (prostate), and HCT116 and HT29 (colorectal). In addition, the study compared this survival-based indicator with molecular repair kinetics assessed through γH2AX and 53BP1 foci clearance. Approach. By using a phenomenological approach, we assessed sublethal damage recovery kinetics, aiming to determine whether this recovery rate could serve as a biomarker for cancer-specific intrinsic radiosensitivity. Cells were subjected to split-dose 4 Gy irradiation delivered in two fractions of 2 Gy across a 0 to 10 h inter-fraction interval range using a Multi-Rad x-ray irradiator with a peak tube voltage of 225 kV. The clonogenic assay was performed following split-dose irradiation of the experimental groups to assess cell survival. Colonies were fixed, stained, and counted ( ⩾ 50 cells/colony viable threshold) to calculate survival fractions (SFs) from the four independent experimental runs completed for each cell line. Unirradiated control cells were used to calculate plating efficiency. The measured SF as a function of inter-fraction time was fitted with the Lea–Catcheside modified linear-quadratic model with a half-life of sublethal damage repair, T repair SLD , as a free parameter. To compare this approach to molecular DNA repair kinetics, immunofluorescence-based ionizing radiation-induced foci (IRIF) clearance experiments were performed following single 2 Gy irradiation using the same x-ray source. γH2AX and 53BP1 foci were quantified from 0.5 to 24 h post-irradiation, and foci clearance half-lives ( T repair γ H 2 AX and T repair 53 BP 1 ) were determined by single-phase exponential decay fitting. Main results. For all measured cell lines, an increase in SF was observed with increasing inter-fraction time. The estimated T repair SLD varied across cell lines, from 1.07 ± 0.35 h in HT29, to 1.98 ± 0.94 h in HeLa, 2.00 ± 0.30 h in PC3, and 3.58 ± 1.45 h in HCT116, indicating different capacities for sublethal damage repair. A negative correlation was measured between T repair SLD and clonogenic survival at 2 Gy ( SF 2 Gy ) by performing orthogonal distance regression, with a slope of − 350 ± 50 min (p = 0.02). T repair γ H 2 AX and T repair 53 BP 1 ranged from 3 to 11 h, with HT29 showing the fastest foci resolution. However, these molecular repair kinetics times did not significantly correlate with SF 2 Gy (p > 0.05) or follow the same trend as T repair SLD across cell lines. For example, PC3 cells exhibited the slowest foci clearance, whereas HCT116 displayed the slowest T repair SLD , suggesting that IRIF-based measurements do not reliably reflect functional sublethal damage repair. Significance. Clonogenic survival assays capture the integrated biological outcome of radiation exposure, reflecting not only DNA damage recognition and repair but also downstream processes such as checkpoint activation, chromatin context, and long-term proliferative capacity. In contrast, molecular readouts like γH2AX and 53BP1 foci clearance, though rapid and widely used, may not fully account for defects in damage response pathways. The observed discrepancy between foci clearance kinetics and survival-based repair rates in this study highlights the limitations of foci quantification as a surrogate for radiosensitivity. These findings underscore the value of survival-based sublethal damage recovery measurements as functionally rich indicators of intrinsic radiosensitivity, which may inform future biomarker development or predictive modeling frameworks.